Therapeutic drug monitoring has a key role in improving patient outcomes, preventing increasing prevalence of antifungal azole resistance and minimising toxicity, but studies have shown widespread prevalence of subtherapeutic azole levels in CF, potentially resulting in ineffective CFTR modulator therapeutic dosing [68–71]. Here, CFTR is linked to cystic fibrosis.